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OBJECTIVES: The Acute Bronchitis Symptom Severity
(ABSS) Scale is a new 7-item, 5-point Likert-scaled patient
reported outcomes instrument designed to capture symp-
toms of acute exacerbations of chronic bronchitis (AECB)
and their impact on functioning. In a multi-site interna-
tional randomized controlled trial comparing a 5-day oral
moxiﬂoxacin (MXF) course to that of a 7-day standard
oral antibiotic regimen (amoxicillin, clarithromycin, 
or cefuroxime-axetil) in the treatment of AECB (the
MOSAIC trial), the ABSS demonstrated good psychome-
tric properties and the ability to detect clinically mean-
ingful change over time. Higher ABSS scores indicate
poorer clinical status. A score drop of 0.7 point (18% of
scale score) is associated with clinical improvement as
rated by the clinician. The contribution of speciﬁc clini-
cal factors to ABSS score is not yet known, however.
METHODS: To assess the contribution of clinical factors
to ABSS score during an exacerbation episode, a multi-
variable ordinary least squares regression equation was
analyzed and the contribution of each variable to overall
adjusted R2 was evaluated. Indicators of chronic bron-
chitis severity used as independent variables were age
(</≥65 years), gender, use of either long-term inhaled
steroids or systemic steroids during the study period with
no change in dose regimen for acute episode (yes/no),
duration of chronic bronchitis (</≥15 years), number of
exacerbations in prior year (</≥4), and baseline FEV1
(</≥50% predicted); ABSS score the dependent variable.
RESULTS: Adjusted model R2 was 0.068. FEV1 con-
tributes approximately 40% of total R2 (p < 0.01) fol-
lowed by use of steroids (p < 0.01) and female gender 
(p < 0.01), which both relate to ABSS score. CONCLU-
SIONS: Results support a relationship between an 
objective measure of lung function and patient report
about bronchitis symptoms and their impact on daily
activities.
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OBJECTIVE: Assess the performance of the newly devel-
oped Health Related Productivity Questionnaire-Diary
(HRPQ-D). METHODS: A multi-center observational
clinical study on patients suffering from infectious
mononucleosis was conducted between January and
April, 2001. Patients completed the HRPQ-D daily for
one-week periods during weeks 1, 2, 4, and 8. Weekly
productivity loss was measured as absenteeism (sum of
the number of hours missed), presenteesim (productivity
decreases due to reduced effectiveness), and combined
lost productivity (absenteeism plus presenteeism) for
three work venues (work outside home, housework, and
classes/homework). Validation was conducted by corre-
lating the productivity measures with the patient-reported
severity of seven symptoms. The responsiveness of the
HRPQ-D was also assessed by correlating the change in
productivity scores and the change in symptom severity
scores between study weeks. RESULTS: A total of 42
patients were enrolled in the study. Symptom scores 
were positively correlated with lost work hours due to
absenteeism and combined lost productivity scores. The
symptom score had a strong correlation with the com-
bined lost productivity across all venues (r = 0.577),
which was mainly driven by the symptom score’s strong
correlation with absenteeism across all venues (r = 0.680).
Perhaps owing to the age groups affected by infectious
mononucleosis, school productivity was particularly well
correlated with symptom severity. Statistically signiﬁcant
correlations to symptom scores were observed in weeks
2 and 4 for school absenteeism (r = 0.438 and r = 0.531,
respectively). The signiﬁcant correlation values between
the change in symptom scores and change in productiv-
ity scores for all week combinations ranged from a low
of -0.161 for presenteeism across all venues to a high 
of 0.422 for school absenteeism. CONCLUSIONS:
The HRPQ-D demonstrated good construct validity and
responsiveness, making it a useful tool for determining
productivity levels across different work venues within
clinical trial or survey research applications.
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OBJECTIVES: Utility calculation generally relies on the
use of generic measures that assess health status. Evidence
suggests that such measures have limited responsive-
ness—largely because the health states described are of
limited relevance to any speciﬁc disease. Quality of life
(QoL) assessment has shown that it is not health status
itself that is important to patients but the impact that this
might have on their lives. Consequently, it would appear
more appropriate for utility to be determined by prefer-
ence for different QoL states, particularly in Quality
Adjusted Life Year (QALY) type analyses. The present
